跳转至内容
Merck

SML2358

Sigma-Aldrich

D-NMAPPD

≥98% (HPLC)

别名:

(1R, 2R)-N-myristoylamino-4′-nitro-phenylpropandiol-1, 3, (1R,2R)-B13, B13, N-[(1R,2R)-2-Hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]tetradecanamide, [R-(R*,R*)]-N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-tetradecanamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H38N2O5
CAS号:
分子量:
422.56
MDL號碼:
分類程式碼代碼:
12352200

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -28 to -34, c = 0.1 in chloroform-d

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C23H38N2O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-22(27)24-21(18-26)23(28)19-14-16-20(17-15-19)25(29)30/h14-17,21,23,26,28H,2-13,18H2,1H3,(H,24,27)/t21-,23-/m1/s1

InChI 密鑰

XUSDVLHKNBOGJY-FYYLOGMGSA-N

生化/生理作用

D-NMAPPD (B13), a myristoyl-CoA analog, is a cell penetrant inhibitor of N-myristoyltransferases that suppressed FRS2α (fibroblast growth factor receptor substrate 2) myristoylation. D-NMAPPD inhibits wild-type FGFRs and drug-resistant mutants (FGFRsDRM) oncogenic signaling in cancer cells. D-NMAPPD potently inhibits growth of xenograft tumors in mice. D-NMAPPD is a potent inhibitor of ceramidase that elevates endogenous ceramide levels and suppress growth of cancer cells.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mototeru Yamane et al.
Biochemistry and biophysics reports, 11, 174-181 (2017-09-29)
In this study, we showed that the dual addition of glucosyl ceramide synthase and ceramidase inhibitors to A549 cell culture led to the possibility of ceramide channel formation via endogenous palmitoyl-ceramide accumulation with an increase in cholesterol contents in the
Qianjin Li et al.
The Journal of biological chemistry, 293(17), 6434-6448 (2018-03-16)
Fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling facilitates tumor initiation and progression. Although currently approved inhibitors of FGFR kinase have shown therapeutic benefit in clinical trials, overexpression or mutations of FGFRs eventually confer drug resistance and thereby abrogate the desired

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门